TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28770409
Drug: Trigger Point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigger Point (TP) therapy combined with Lymphatic Drainage (LD)
Study: 25998450
Drug: Neridronate 100
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neridronate 100 mg given four times over 10 days
Study: 21842171
Drug: sugammadex (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugammadex (2 mg/kg)
Study: 21842171
Drug: neostigmine (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: neostigmine (0.04 mg/kg)
Study: 19024312
Drug: Pulmonary static
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary static inflation during CPB, no sevoflurane inhaled
Study: 10755499
Drug: E5 (murine
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5 (murine monoclonal antibody directed against endotoxin, 2 mg/kg per day by intravenous infusion 24 hours apart)
Study: 1421737
Drug: Lidocaine 70
Normalized name: lidocaine 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 70 mg
Study: 3903784
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g triletide per day
Study: 3903786
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g cimetidine per day
Study: 31639529
Drug: FORNET (adapted
Approvals — FDA: no, EMA: no, PMDA: no
Description: FORNET (adapted Narrative Exposure Therapy)
Study: 18058305
Drug: Betamethasone %1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone %1 cream
Study: 18058305
Drug: Unna's Boot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unna's Boot cream
Study: 15851794
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa therapy
Study: 9802367
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 micro(g) once daily
Study: 9802367
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) 200 micro(g) once daily
Study: 9802367
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (TAA) 220 micro(g) once daily
Study: 7713046
Drug: F2 (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: F2 (2.0 g/100 ml protein formula)
Study: 7713046
Drug: F1.5 (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: F1.5 (1.5 g/100 ml protein formula)
Study: 28259556
Drug: Moxidectin pour-on
Normalized name: doramectin
DrugBank: Doramectin (DB11400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxidectin pour-on (Cydectin® 0.5% Pour-On, Zoetis) administered during the dry period (7–77 days before parturition) to 638 animals
Study: 26012937
Drug: Salmon calcitonin
Normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon calcitonin treatment in addition to calcium and vitamin D (Group I)
Study: 23571802
Drug: Percutaneous irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous irradiation therapy
Study: 22462232
Drug: Oral entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral entecavir
Study: 19198872
Drug: Fluid controlling
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid controlling hormones (Antidiuretic hormone and aldosterone)
Study: 16432056
Drug: Antithrombotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy (Warfarin or Aspirin)
Study: 9045347
Drug: Carboplatin administered
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin administered over 30 minutes and paclitaxel over 3 hours, every 4 weeks
Study: 9045347
Drug: Increasing paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Increasing paclitaxel doses from 100 to 250 mg/m2
Study: 7904761
Drug: ipsapirone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipsapirone (10 mg to 30 mg daily)
Study: 7904761
Drug: lorazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazepam (2 mg to 6 mg daily)
Study: 30765508
Drug: Omipalisib (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omipalisib (0.25 mg, 1 mg, and 2 mg twice daily for 8 days)
Study: 30073929
Drug: PEM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEM therapy (Serrazyme and other constituents) for 2 months
Study: 19770635
Drug: Capecitabine (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (2000 mg/m/day for 14 days, once every 3 weeks) plus erlotinib (150 mg/day)
Study: 19770635
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m as a 30-min infusion) plus erlotinib (150 mg/day)
Study: 16037756
Drug: Phytoestrogen-containing supplement
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytoestrogen-containing supplement (soy isoflavones and Actaea racemosa)
Study: 10460765
Drug: Double patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double patch with tape
Study: 10460765
Drug: No patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: No patch with tape
Study: 8532911
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus hormone therapy
Study: 2092324
Drug: calcitonin (415
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcitonin (415 pmol i.v. bolus + continuous infusion during 90 min to reach an overall dose of 62.25 pmol.kg‐1 body mass)
Study: 353458
Drug: Spironolactone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (50 mg twice a day)
Study: 353458
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 mg twice a day)
Study: 353458
Drug: Spironolactone +
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone + alpha-methyldopa (250 mg three times a day)
Study: 353458
Drug: Hydrochlorothiazide +
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide + alpha-methyldopa (250 mg three times a day)
Study: 30509553
Drug: iCook 4-H
Normalized name: egg shell, cooked
Approvals — FDA: no, EMA: no, PMDA: no
Description: iCook 4-H treatment group
Study: 19040678
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium extended-release 1000 mg daily after initial 500 mg for 15 days
Study: 17062029
Drug: Pulse itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulse itraconazole (200 mg twice daily, 1 week on, 3 weeks off, for 12 weeks)
Study: 17062029
Drug: Continuous terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous terbinafine (250 mg once daily for 12 weeks)
Study: 9666777
Drug: Transurethral alprostadil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral alprostadil therapy
Study: 3261548
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg administered sublingually one minute before anaesthetic induction
Study: 28807988
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (flow 50 L/min, FIO2 0.5)
Study: 25055809
Drug: Pre-treatment cortico-striatal
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment cortico-striatal connectivity
Study: 22006106
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy for 5 weeks
Study: 16457716
Drug: Buprenorphine patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine patch
Study: 14510796
Drug: Contact-topical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contact-topical anaesthesia
Study: 14510796
Drug: Peribulbar injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peribulbar injection anaesthesia
Study: 8970271
Drug: Dexamethasone iontophoresis
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone iontophoresis (1 ml of DEX at 4 mg/ml mixed with 1 ml of sterile water)
Study: 8970271
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 ml of saline solution)
Study: 6094444
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic antibiotic
Study: 27713964
Drug: Inositol-enriched beverage
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inositol-enriched beverage (IEB) (2.0 g twice a day)
Study: 18008121
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg droperidol intravenously
Study: 17459901
Drug: l‐NMMA 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: l‐NMMA 0.15 mg/kg
Study: 17459901
Drug: l‐NMMA 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: l‐NMMA 0.5 mg/kg
Study: 17459901
Drug: l‐NMMA 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: l‐NMMA 1.0 mg/kg
Study: 17459901
Drug: l‐NMMA 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: l‐NMMA 1.5 mg/kg
Study: 11196401
Drug: Randomized Controlled
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized Controlled Trials in Medicine
Study: 8853216
Drug: Nefazodone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (400 mg daily)
Study: 1535321
Drug: Inhaled ipratropium
Normalized name: ipratropium Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ipratropium bromide (40 micrograms)
Study: 22541894
Drug: Twice-daily 75%/25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily 75%/25% neutral protamine lispro/lispro mix
Study: 22541894
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily insulin glargine
Study: 22541894
Drug: Both insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both insulin regimens
Study: 15817864
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg vitamin C/d
Study: 19057523
Drug: Lorcaserin 10
Normalized name: lorcaserin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin 10 mg q.d.
Study: 19057523
Drug: Lorcaserin 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin 15 mg q.d.
Study: 19057523
Drug: Lorcaserin 10
Normalized name: lorcaserin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin 10 mg b.i.d.
Study: 24144215
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol 15 mg/kg
Study: 17474540
Drug: Propacetamol 30
Normalized name: Propanetriol
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol 30 mg/kg
Study: 8124988
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous zinc therapy
Study: 8124988
Drug: Supplemental intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental intravenous zinc therapy
Study: 2535873
Drug: MMR vaccine
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR vaccine with varicella vaccine
Study: 2535873
Drug: MMR vaccine
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR vaccine with placebo
Study: 22581848
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Methylphenidate (MPH)
Study: 20836726
Drug: OC containing
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC containing 35 μg ethinylestradiol plus 2 mg cyproterone acetate
Study: 20836726
Drug: OC containing
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC containing 30 μg ethinylestradiol plus 3 mg drospirenone
Study: 20836726
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg × 2
Study: 20836726
Drug: OC treatment
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC treatment (both groups A and B)
Study: 8757208
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg once daily for 6 weeks
Study: 1374266
Drug: Aprotinin (560
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (560 mg; n = 10)
Study: 27429724
Drug: Triamcinolone ointment
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone ointment and zinc-containing mouthwash
Study: 27429724
Drug: Triamcinolone ointment
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone ointment alone
Study: 22795360
Drug: LLPR system
Approvals — FDA: no, EMA: no, PMDA: no
Description: LLPR system (interactive video game-based rehabilitation) for lower limb muscle power training, 30-min training, twice a week for 6 weeks (12 sessions)
Study: 11956124
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid at 5 mg/m2
Study: 7697954
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg immediate-release alprazolam
Study: 7697954
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg extended-release alprazolam
Study: 7697954
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg extended-release alprazolam
Study: 7697954
Drug: Immediate-release alprazolam
Normalized name: alprazolam Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release alprazolam (both doses)
Study: 7697954
Drug: Extended-release alprazolam
Normalized name: alprazolam Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release alprazolam (both doses)
Study: 385023
Drug: Labetalol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (600 mg/day)
Study: 385023
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Labetalol and Bendrofluazide)
Study: 29040119
Drug: Biomaterial-free cultured
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomaterial-free cultured oral mucosal epithelial cell sheets (COMECs)
Study: 26932802
Drug: Pomalidomide 4
Normalized name: pomalidomide 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 4 mg on days 1 to 21 of a 28‐day cycle with weekly dexamethasone (arm B)
Study: 26932802
Drug: Pomalidomide, dexamethasone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide, dexamethasone, and cyclophosphamide (PomCyDex) 400 mg orally on days 1, 8, and 15 (arm C)
Study: 23134528
Drug: Letrozole/antagonist protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole/antagonist protocol (mild stimulation)
Study: 23134528
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist protocol (microdose flare)
Study: 18467673
Drug: Prednisone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (2 mg/kg)
Study: 16814257
Drug: Ethyl-eicosapentanoate (EPA)
Normalized name: Ethyl Acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl-eicosapentanoate (EPA) 6 g/day
Study: 8959788
Drug: Misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (200 micrograms four times daily)
Study: 1493985
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg twice daily for three days
Study: 30123250
Drug: Action Observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Action Observation Treatment (AOT)
Study: 31981294
Drug: Videogame Observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videogame Observation Treatment (VOT)
Study: 29174128
Drug: IUI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IUI with ovarian stimulation (oral clomifene citrate 50-150 mg or oral letrozole 2.5-7.5 mg, days 2-6)
Study: 25495953
Drug: Nebivolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (5 mg/d) for 8 weeks
Study: 23128104
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (1-g capsules containing ≥840 mg n-3-PUFAs as ethyl esters) with preoperative loading of 10 g over 3 to 5 days followed by 2 g/d until hospital discharge or postoperative day 10.
Study: 16858958
Drug: Oxcarbazepine 600
Normalized name: oxcarbazepine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine 600 mg/d
Study: 16858958
Drug: Oxcarbazepine 1200
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine 1200 mg/d
Study: 12456910
Drug: Pimecrolimus (Elidel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimecrolimus (Elidel, SDZ ASM 981) cream 1%
Study: 12456910
Drug: Pimecrolimus (Elidel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimecrolimus (Elidel, SDZ ASM 981) cream 1% (after all patients switched at week 6)
Study: 10878516
Drug: Oral ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ofloxacin (400 mg every 12 hours)
Study: 10878516
Drug: Intravenous imipenem-cilastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous imipenem-cilastatin (500 mg every 6 hours)
Study: 20850296
Drug: Primary debulking
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary debulking surgery followed by chemotherapy
Study: 16518708
Drug: Ciprofloxacin 1000
Normalized name: ciprofloxacin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 1000 mg extended-release once-daily
Study: 16518708
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg immediate-release twice-daily
Study: 7798614
Drug: RA treatment
Normalized name: RAS
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RA treatment
Study: 7798614
Drug: Anti-CD11c antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-CD11c antibody
Study: 24781571
Drug: Subcutaneous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous saline injection to increase arterial depth from <2 mm to 2-4 mm
Study: 24781571
Drug: Subcutaneous arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous arterial depth of 2-4 mm
Study: 20227301
Drug: Sildenafil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil at 40 mg 3 times daily
Study: 19326341
Drug: Double-dose antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose antioxidant supplement
Study: 10197402
Drug: Standard ignoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ignoring treatment
Study: 10197402
Drug: Graduated ignoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graduated ignoring treatment
Study: 2132137
Drug: Bretylium 10
Normalized name: bretylium 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bretylium 10 mg/kg
Study: 358527
Drug: Oxybutynin chloride
Normalized name: Oxybutynin Chloride
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxybutynin chloride 10 mg
Study: 358527
Drug: Oxybutynin chloride
Normalized name: Oxybutynin Chloride
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxybutynin chloride 20 mg
Study: 28778550
Drug: Carbohydrate‐electrolyte‐protein solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate‐electrolyte‐protein solution (CEP)
Study: 26032216
Drug: Electrically induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrically induced muscle cramps (EIMCs) applied twice a week, 3x6 EIMCs of 5 seconds each
Study: 22788697
Drug: Tacrolimus 0.1%
Normalized name: TACROLIMUS 0.1% OINT,TOP
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus 0.1% ointment applied to affected nails for 12 weeks
Study: 21775557
Drug: Leucine-enriched essential
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine-enriched essential amino acids (L-EAA) - 10 g EAA with 3.5 g leucine
Study: 21775557
Drug: Essential amino
Normalized name: Essential amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential amino acids (EAA) - 10 g EAA with 1.87 g leucine
Study: 8783540
Drug: Saline alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline alone for maintenance of peripheral intravenous access devices
Study: 8783540
Drug: Heparinized saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparinized saline for maintenance of peripheral intravenous access devices
Study: 6714820
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Orgotein and Corticoid)
Study: 30064991
Drug: GM-CSF (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF (3 μg/kg/day), subcutaneous, once daily for 4 days
Study: 24579075
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (Lactobacillus acidophilus, Lactobacillus delbrueckii subsp. bulgaricus, and Bifidobacterium bifidus)
Study: 22514718
Drug: Non-pharmaceutical interventions
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmaceutical interventions (NPIs)
Study: 18457471
Drug: Alfimeprase (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfimeprase (0.3 mg/kg)
Study: 16076989
Drug: Green tea‐caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea‐caffeine mixture (270 mg epigallocatechin gallate + 150 mg caffeine per day)
Study: 12399201
Drug: 0.6 micro
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 micro g of purified non‐adsorbed hepatitis B surface antigen (HBsAg)
Study: 12399201
Drug: 3.5 micro
Normalized name: neomycin sulfate 3.5 MICROGRAM In 1 GRAM / polymyxin B sulfate 10000 UNITS In 1 GRAM / bacitracin zinc 400 UNITS In 1 GRAM OPHTHALMIC OINTMENT [Neosporin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 micro g of purified non‐adsorbed hepatitis B surface antigen (HBsAg)